Cipher Pharmaceuticals Stock Performance
| CPH Stock | CAD 14.75 0.05 0.34% |
Cipher Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cipher Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cipher Pharmaceuticals is expected to be smaller as well. Cipher Pharmaceuticals right now shows a risk of 2.17%. Please confirm Cipher Pharmaceuticals total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Cipher Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cipher Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy technical indicators, Cipher Pharmaceuticals is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
1 | Stock Evaluation Report - news.stocktradersdaily.com | 10/30/2025 |
2 | How Cipher Pharmaceuticals Inc. stock valuation compares with sector - 2025 Technical Patterns Risk Controlled Swing Alerts - newser.com | 11/07/2025 |
3 | Stifel Maintains Cipher Pharmaceuticals Inc With Buy Rating, Cuts Target Price to 14.52 - | 11/12/2025 |
4 | Will Cipher Pharmaceuticals Inc. stock keep raising dividends - Insider Selling Stock Portfolio Risk Management - newser.com | 11/19/2025 |
5 | Stock Trading Blueprint - news.stocktradersdaily.com | 12/09/2025 |
6 | Are Strong Financial Prospects The Force That Is Driving The Momentum In Cipher Pharmaceuticals Inc.s TSECPH Stock - simplywall.st | 12/23/2025 |
7 | Long Term Investment Analysis - Stock Traders Daily | 01/13/2026 |
| Begin Period Cash Flow | 39.8 M | |
| Total Cashflows From Investing Activities | -80 M |
Cipher |
Cipher Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,432 in Cipher Pharmaceuticals on October 30, 2025 and sell it today you would earn a total of 43.00 from holding Cipher Pharmaceuticals or generate 3.0% return on investment over 90 days. Cipher Pharmaceuticals is generating 0.0719% of daily returns assuming 2.1718% volatility of returns over the 90 days investment horizon. Simply put, 19% of all stocks have less volatile historical return distribution than Cipher Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cipher Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Cipher Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.75 | 90 days | 14.75 | about 37.77 |
Based on a normal probability distribution, the odds of Cipher Pharmaceuticals to move above the current price in 90 days from now is about 37.77 (This Cipher Pharmaceuticals probability density function shows the probability of Cipher Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Cipher Pharmaceuticals has a beta of 0.14 suggesting as returns on the market go up, Cipher Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cipher Pharmaceuticals will be expected to be much smaller as well. Additionally Cipher Pharmaceuticals has an alpha of 0.0335, implying that it can generate a 0.0335 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cipher Pharmaceuticals Price Density |
| Price |
Predictive Modules for Cipher Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cipher Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cipher Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cipher Pharmaceuticals is not an exception. The market had few large corrections towards the Cipher Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cipher Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cipher Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.14 | |
σ | Overall volatility | 0.61 | |
Ir | Information ratio | -0.01 |
Cipher Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cipher Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cipher Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cipher Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| The company has C$40.58 Million in debt which may indicate that it relies heavily on debt financing | |
| About 43.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Long Term Investment Analysis - Stock Traders Daily |
Cipher Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cipher Stock often depends not only on the future outlook of the current and potential Cipher Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cipher Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.6 M | |
| Cash And Short Term Investments | 17.8 M |
Cipher Pharmaceuticals Fundamentals Growth
Cipher Stock prices reflect investors' perceptions of the future prospects and financial health of Cipher Pharmaceuticals, and Cipher Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cipher Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.053 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 382.28 M | ||||
| Shares Outstanding | 25.37 M | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 7.48 X | ||||
| Revenue | 33.36 M | ||||
| Gross Profit | 37.2 M | ||||
| EBITDA | 11.87 M | ||||
| Net Income | 11.54 M | ||||
| Cash And Equivalents | 17.84 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 40.58 M | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 6.16 X | ||||
| Cash Flow From Operations | 19.55 M | ||||
| Earnings Per Share | 0.92 X | ||||
| Market Capitalization | 374.56 M | ||||
| Total Asset | 162.51 M | ||||
| Retained Earnings | 77.65 M | ||||
| Working Capital | 18.61 M | ||||
About Cipher Pharmaceuticals Performance
By examining Cipher Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Cipher Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cipher Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 262.55 | 239.82 | |
| Return On Tangible Assets | 0.17 | 0.16 | |
| Return On Capital Employed | 0.05 | 0.05 | |
| Return On Assets | 0.06 | 0.07 | |
| Return On Equity | 0.10 | 0.11 |
Things to note about Cipher Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cipher Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cipher Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cipher Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| The company has C$40.58 Million in debt which may indicate that it relies heavily on debt financing | |
| About 43.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Long Term Investment Analysis - Stock Traders Daily |
- Analyzing Cipher Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cipher Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cipher Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cipher Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cipher Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cipher Pharmaceuticals' stock. These opinions can provide insight into Cipher Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.